https://www.biopharmawatch.com/news/LFMD/lifemd-reschedules-q3-2026-earnings-call BiopharmaWatch en 2026-11-07T00:25:00.000Z LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026 https://www.biopharmawatch.com/news/BFRI/biofrontera-third-quarter-2026-results BiopharmaWatch en 2026-11-06T23:08:00.000Z Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026 https://www.biopharmawatch.com/news/ANGO/angiodynamics-inducement-grants-ceo-appointment BiopharmaWatch en 2026-11-06T23:00:00.000Z AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-q3-2026-results BiopharmaWatch en 2026-11-06T22:40:00.000Z bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization https://www.biopharmawatch.com/news/SRZN/surrozen-present-upcoming-healthcare-investor-conference-20261106 BiopharmaWatch en 2026-11-06T21:40:00.000Z Surrozen to Present at Upcoming Healthcare Investor Conference https://www.biopharmawatch.com/news/SNWV/sanuwave-conference-call-q3-2026-results BiopharmaWatch en 2026-11-06T21:30:00.000Z Sanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results https://www.biopharmawatch.com/news/MDCX/medicus-pharma-q3-2026-financial-results-update BiopharmaWatch en 2026-11-06T21:30:00.000Z Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:30:00.000Z ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/JAGX/jaguar-health-special-meeting-approval-2026 BiopharmaWatch en 2026-11-06T21:15:00.000Z Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders https://www.biopharmawatch.com/news/ENTX/entera-announces-q3-2026-financial-results BiopharmaWatch en 2026-11-06T21:15:00.000Z Entera Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/CDNA/caredx-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KARD/kardigan-phase-2b-katalyst-av-trial-enrollment-complete BiopharmaWatch en 2026-11-06T21:05:00.000Z Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-nasdaq-rule BiopharmaWatch en 2026-11-06T21:05:00.000Z Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-inducement-awards-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z Spyre Therapeutics Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/ICCC/immucell-announces-q3-2026-financial-results BiopharmaWatch en 2026-11-06T21:05:00.000Z ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-merger-mentari-therapeutics BiopharmaWatch en 2026-11-06T21:05:00.000Z InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T21:05:00.000Z LeMaitre to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NTLA/intellia-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-11-06T21:05:00.000Z Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-conference-call-vrdn-008-phase-1-data BiopharmaWatch en 2026-11-06T21:01:00.000Z Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-webcast-nkx019-acr-convergence-2026 BiopharmaWatch en 2026-11-06T21:01:00.000Z Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:01:00.000Z BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:01:00.000Z NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INAB/in8bio-stock-option-inducement-grant BiopharmaWatch en 2026-11-06T21:01:00.000Z IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/FTH/faeth-report-pik-201-phase-2-data-event-november-9-2026 BiopharmaWatch en 2026-11-06T21:00:00.000Z Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026 https://www.biopharmawatch.com/news/IMNM/immunome-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261106 BiopharmaWatch en 2026-11-06T21:00:00.000Z Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BMY/bmy-phase-3-data-camzyos-pediatric-ohcm BiopharmaWatch en 2026-11-06T21:00:00.000Z Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T21:00:00.000Z Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BRVE/braveheart-bio-hengrui-pharma-hrs-bhb-1893-data BiopharmaWatch en 2026-11-06T20:15:00.000Z Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/ACOG/alpha-cognition-investor-events-participation BiopharmaWatch en 2026-11-06T20:00:00.000Z Alpha Cognition to Participate in Upcoming Investor Events https://www.biopharmawatch.com/news/ALGN/align-technology-extel-2026-rankings BiopharmaWatch en 2026-11-06T17:59:00.000Z Align Technology Recognized in Extel’s 2026 All-America Executive Team Rankings https://www.biopharmawatch.com/news/GILD/lenacapavir-hiv-prevention-trial-results BiopharmaWatch en 2026-11-06T17:16:00.000Z New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-phase-1-2a-study-melanoma BiopharmaWatch en 2026-11-06T17:00:00.000Z Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-2-trial-brenetafusp-kimmtrak BiopharmaWatch en 2026-11-06T17:00:00.000Z Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma https://www.biopharmawatch.com/news/CHE/chemed-quarterly-dividend-announcement BiopharmaWatch en 2026-11-06T16:23:00.000Z Chemed Corporation Declares Quarterly Dividend of 70 Cents https://www.biopharmawatch.com/news/HCWB/hcw-biologics-hcw11-040-sitc-presentation BiopharmaWatch en 2026-11-06T16:00:00.000Z HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer https://www.biopharmawatch.com/news/EVAX/evax-01-phase-2-trial-results BiopharmaWatch en 2026-11-06T16:00:00.000Z New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/INCY/2026-ingenuity-awards-gvhd-recipients BiopharmaWatch en 2026-11-06T15:40:00.000Z 2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute https://www.biopharmawatch.com/news/OSRH/osr-health-exercises-15-million-vxm01-equity-option BiopharmaWatch en 2026-11-06T15:11:00.000Z OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes https://www.biopharmawatch.com/news/HALO/halozyme-reaffirms-projects-zero-minimal-impact-royalty-revenue-through-least BiopharmaWatch en 2026-11-06T15:04:00.000Z Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 https://www.biopharmawatch.com/news/QGEN/qiagen-shareholders-approve-jonathan-pratt BiopharmaWatch en 2026-11-06T15:00:00.000Z QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director https://www.biopharmawatch.com/news/HALO/fda-approves-rybrevant-faspro-halozyme-advanced-cancer BiopharmaWatch en 2026-11-06T14:57:00.000Z U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer https://www.biopharmawatch.com/news/INKT/mink-therapeutics-sitc-2026-data-inkt-therapy BiopharmaWatch en 2026-11-06T14:48:00.000Z MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) https://www.biopharmawatch.com/news/IRTC/irhythm-holdings-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-06T14:15:00.000Z iRhythm Holdings to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HCWB/hcw-biologics-t-cell-engager-sitc-2026 BiopharmaWatch en 2026-11-06T14:15:00.000Z HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting https://www.biopharmawatch.com/news/ALGN/align-technology-270-million-stock-repurchase BiopharmaWatch en 2026-11-06T14:10:00.000Z Align Technology Announces $270 Million Accelerated Stock Repurchase Agreement https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-sitc-presentation-2026 BiopharmaWatch en 2026-11-06T14:05:00.000Z Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) https://www.biopharmawatch.com/news/OBX/obsidian-therapeutics-amsoki-cel-sitc-2026 BiopharmaWatch en 2026-11-06T14:05:00.000Z Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/IMRX/atebimetinib-combinations-ratios-cancer-models-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:37.000Z Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-treatment-survival-mcrc-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 https://www.biopharmawatch.com/news/CADL/candel-therapeutics-sitc-2026-data BiopharmaWatch en 2026-11-06T14:00:00.000Z Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-ctx-10726-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/IMCR/immunocore-q3-2026-financial-results-update BiopharmaWatch en 2026-11-06T14:00:00.000Z Immunocore reports third quarter financial results and provides a business update https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q3-2026-results BiopharmaWatch en 2026-11-06T14:00:00.000Z Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/BCTX/briacell-bria-pro-positive-preclinical-data-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 https://www.biopharmawatch.com/news/IMNN/imnn-001-activates-t-cell-immunity-advanced-ovarian-cancer BiopharmaWatch en 2026-11-06T14:00:00.000Z IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-q3-2026-revenue-outlook BiopharmaWatch en 2026-11-06T13:30:00.000Z OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook https://www.biopharmawatch.com/news/BCDA/biocardia-completes-pmda-consultation-cardiamp-approval BiopharmaWatch en 2026-11-06T13:30:00.000Z BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video BiopharmaWatch en 2026-11-06T13:30:00.000Z Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-06T13:30:00.000Z CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 https://www.biopharmawatch.com/news/ICUI/icu-medical-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-11-06T13:30:00.000Z ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-q3-2026-results BiopharmaWatch en 2026-11-06T13:15:00.000Z CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ACRV/acrivon-expands-immunology-inflammation-acquisition-phase-2-ready-differentiated-oral BiopharmaWatch en 2026-11-06T13:00:30.000Z Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB https://www.biopharmawatch.com/news/ACRV/acrivon-acquires-acr-525-jak1-inhibitor BiopharmaWatch en 2026-11-06T13:00:30.000Z Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB https://www.biopharmawatch.com/news/ASND/transcon-cnp-market-exclusivity-eu-approval BiopharmaWatch en 2026-11-06T13:00:00.000Z Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union https://www.biopharmawatch.com/news/ENGN/engene-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z enGene to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-nasdaq-listing-rule-5635-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MDXG/mimedx-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z MIMEDX to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-business-progress-q3-2026 BiopharmaWatch en 2026-11-06T13:00:00.000Z Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-06T13:00:00.000Z Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/IART/integra-lifesciences-2026-ubs-global-healthcare-conference BiopharmaWatch en 2026-11-06T13:00:00.000Z Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference https://www.biopharmawatch.com/news/NHC/nhc-reports-third-quarter-2026-earnings BiopharmaWatch en 2026-11-06T12:30:00.000Z NHC Reports Third Quarter 2026 Earnings https://www.biopharmawatch.com/news/SNGX/soligenix-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T12:30:00.000Z Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EHC/encompass-health-sea-pines-hospital-closure BiopharmaWatch en 2026-11-06T12:30:00.000Z Encompass Health announces indefinite closure of Sea Pines Rehabilitation Hospital due to flood damage https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-surgeon-guided-autonomy-intelligent-surgery BiopharmaWatch en 2026-11-06T12:30:00.000Z Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery https://www.biopharmawatch.com/news/DAVI/davion-healthcare-appoints-vienna-capital-partners BiopharmaWatch en 2026-11-06T12:30:00.000Z Davion Healthcare Plc Appoints Vienna Capital Partners to Support US$100 Million Acquisition Financing Strategy https://www.biopharmawatch.com/news/IFRX/inflarx-phase-1-data-izicopan-safety-profile BiopharmaWatch en 2026-11-06T12:30:00.000Z InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T12:30:00.000Z Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CANF/can-fite-pursue-global-licensing-strategic-partnerships-bio-europe-2026 BiopharmaWatch en 2026-11-06T12:23:00.000Z Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones https://www.biopharmawatch.com/news/CANF/can-fite-global-licensing-bio-europe-2026 BiopharmaWatch en 2026-11-06T12:23:00.000Z Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones https://www.biopharmawatch.com/news/NEO/neogenomics-participate-investor-conferences BiopharmaWatch en 2026-11-06T12:05:00.000Z NeoGenomics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HLF/herbalife-participate-stephens-investment-conference BiopharmaWatch en 2026-11-06T12:05:00.000Z Herbalife to Participate in 1 on 1 Meetings at Stephens Annual Investment Conference on November 19 https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T12:05:00.000Z Anika Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-q3-2026-results BiopharmaWatch en 2026-11-06T12:05:00.000Z Treace Medical Concepts Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-tailorplasty-surgical-cases BiopharmaWatch en 2026-11-06T12:04:00.000Z Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction System https://www.biopharmawatch.com/news/CGC/canopy-growth-q2-fy2027-financial-results BiopharmaWatch en 2026-11-06T12:03:08.000Z Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-precise-btn-results-ata-meeting BiopharmaWatch en 2026-11-06T12:00:00.000Z Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting https://www.biopharmawatch.com/news/BHC/bausch-health-salix-liver-meeting-2026 BiopharmaWatch en 2026-11-06T12:00:00.000Z Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/EYPT/eyepoint-participation-investor-conferences-scientific-meetings BiopharmaWatch en 2026-11-06T12:00:00.000Z EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T12:00:00.000Z Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KRRO/korro-presents-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-06T12:00:00.000Z Korro to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/GUTS/fractyl-health-q3-2026-financial-results BiopharmaWatch en 2026-11-06T12:00:00.000Z Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 https://www.biopharmawatch.com/news/MSLE/satellos-changes-efficacy-endpoint-basecamp-trial BiopharmaWatch en 2026-11-06T12:00:00.000Z Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback https://www.biopharmawatch.com/news/LLY/lilly-hims-hers-expand-access-fda-approved-medicines BiopharmaWatch en 2026-11-06T11:47:00.000Z Lilly and Hims & Hers expand access to FDA-approved Lilly medicines https://www.biopharmawatch.com/news/AIRS/airsculpt-technologies-q3-fiscal-2026-results BiopharmaWatch en 2026-11-06T11:45:27.000Z AirSculpt Technologies Reports Third Quarter Fiscal 2026 Results https://www.biopharmawatch.com/news/MRNA/moderna-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-06T11:45:00.000Z Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/BKD/brookdale-announces-third-quarter-2026-results BiopharmaWatch en 2026-11-06T11:30:00.000Z Brookdale Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/VOGX/vogenx-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-06T11:30:00.000Z Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q3-2026-results BiopharmaWatch en 2026-11-06T11:27:00.000Z Elanco Animal Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ELAN/elanco-pet-health-consumer-research-october-2026 BiopharmaWatch en 2026-11-06T11:27:00.000Z October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-06T10:50:00.000Z Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/RARE/ultragenyx-maa-ux111-review-mhra BiopharmaWatch en 2026-11-06T08:30:00.000Z Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) https://www.biopharmawatch.com/news/MOLN/molecular-partners-preclinical-data-mp0632-sitc-2026 BiopharmaWatch en 2026-11-06T06:00:08.000Z Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026 https://www.biopharmawatch.com/news/PHAR/mhra-approves-pharming-joenja-treatment-children-apds BiopharmaWatch en 2026-11-06T06:00:00.000Z MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. https://www.biopharmawatch.com/news/INO/inovio-pricing-75-million-public-offering BiopharmaWatch en 2026-11-06T04:18:00.000Z INOVIO Announces Pricing of Approximately $75 Million Public Offering https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-public-offering-pricing BiopharmaWatch en 2026-11-06T03:42:00.000Z Orchestra BioMed Announces Pricing of Public Offering https://www.biopharmawatch.com/news/JNJ/fda-approval-rybrevant-faspro-head-neck-cancer BiopharmaWatch en 2026-11-06T02:03:00.000Z Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-bamzireotide-trial-data-nanets-2026 BiopharmaWatch en 2026-11-06T01:10:00.000Z Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs https://www.biopharmawatch.com/news/NHC/nhc-announces-common-dividend-20261106 BiopharmaWatch en 2026-11-06T01:00:00.000Z NHC Announces Common Dividend https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-september-2026 BiopharmaWatch en 2026-11-05T22:29:00.000Z Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-earnings BiopharmaWatch en 2026-11-05T22:23:00.000Z CORRECTING and REPLACING Nu Skin Enterprises Reports Third Quarter Earnings https://www.biopharmawatch.com/news/COO/coopercompanies-release-date-fourth-quarter-full-year-2026 BiopharmaWatch en 2026-11-05T22:23:00.000Z CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2026 https://www.biopharmawatch.com/news/MRNA/moderna-mrna-influenza-covid-vaccines-authorization BiopharmaWatch en 2026-11-05T22:20:00.000Z Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-share-repurchase BiopharmaWatch en 2026-11-05T22:15:00.000Z Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases https://www.biopharmawatch.com/news/CTKB/cytek-aurora-evo-award-drug-discovery-innovation BiopharmaWatch en 2026-11-05T22:00:30.000Z Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T22:00:00.000Z Thermo Fisher Scientific Announces Quarterly Dividend https://www.biopharmawatch.com/news/CODX/co-diagnostics-q3-2026-earnings-release BiopharmaWatch en 2026-11-05T22:00:00.000Z Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/BDSX/biodesix-third-quarter-2026-results-highlights BiopharmaWatch en 2026-11-05T21:46:26.538Z Biodesix Announces Third Quarter 2026 Results and Highlights https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:46:00.465Z vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CRIS/curis-q3-2026-results-conference-call BiopharmaWatch en 2026-11-05T21:38:00.000Z Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:34:00.000Z Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MSLE/satellos-investor-call-update-clinical-strategy BiopharmaWatch en 2026-11-05T21:32:00.000Z Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study https://www.biopharmawatch.com/news/MTD/mettler-toledo-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:30:00.000Z Mettler-Toledo International Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-nasdaq-listing-rule-20261105 BiopharmaWatch en 2026-11-05T21:30:00.000Z Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CON/concentra-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:30:00.000Z Concentra Announces Results For Its Third Quarter Ended September 30, 2026 and Raises FY 2026 Guidance https://www.biopharmawatch.com/news/BIOA/bioage-labs-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:30:00.000Z BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/TARS/tarsus-participate-upcoming-investor-conferences-20261105 BiopharmaWatch en 2026-11-05T21:30:00.000Z Tarsus to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ELUT/elutia-reports-q3-2026-results-nxt-41x-fda-submission BiopharmaWatch en 2026-11-05T21:17:00.000Z Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch https://www.biopharmawatch.com/news/ULS/uls-solutions-modernize-life-science-training BiopharmaWatch en 2026-11-05T21:15:00.000Z UL Solutions Collaborates on Cross-Industry Initiative to Modernize Life Science Regulated Training https://www.biopharmawatch.com/news/AMN/amn-healthcare-q3-2026-results BiopharmaWatch en 2026-11-05T21:15:00.000Z AMN HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS https://www.biopharmawatch.com/news/CTMX/cytomx-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:15:00.000Z CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SI/shoulder-innovations-reports-third-quarter-2026-financial-results-raises-full BiopharmaWatch en 2026-11-05T21:11:00.000Z Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook https://www.biopharmawatch.com/news/ACET/adicet-bio-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NEPH/nephros-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Nephros Announces Strong Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-new-ceo-jeannette-bankes BiopharmaWatch en 2026-11-05T21:08:00.000Z Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:07:00.000Z Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-q3-2026-results-ph-762-update BiopharmaWatch en 2026-11-05T21:06:36.000Z Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation https://www.biopharmawatch.com/news/NTRA/natera-announces-leadership-transition BiopharmaWatch en 2026-11-05T21:06:00.000Z Natera Announces Leadership Transition https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-q3-earnings BiopharmaWatch en 2026-11-05T21:06:00.000Z Nu Skin Enterprises Reports Third Quarter Earnings https://www.biopharmawatch.com/news/STLN/starling-oncology-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:06:00.000Z Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-q3-results-2026 BiopharmaWatch en 2026-11-05T21:05:58.000Z AVITA Medical Reports Third Quarter Results https://www.biopharmawatch.com/news/DH/definitive-healthcare-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:58.000Z Definitive Healthcare Reports Financial Results for Third Quarter 2026 https://www.biopharmawatch.com/news/CVRX/cvrx-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:54.000Z CVRx Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CAMP/camp4-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-05T21:05:53.000Z CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:51.000Z Caribou Biosciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/APMD/apnimed-inc-reports-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-05T21:05:51.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/FOCL/focaltherics-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:50.000Z FocalTherics™ Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PROF/profound-medical-q3-2026-results-distribution-expansion BiopharmaWatch en 2026-11-05T21:05:00.000Z Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth https://www.biopharmawatch.com/news/IRTC/irhythm-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z iRhythm Holdings Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RNXT/renovorx-reports-record-q3-2026-revenue BiopharmaWatch en 2026-11-05T21:05:00.000Z RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million https://www.biopharmawatch.com/news/ABCL/abcellera-presentation-ubs-global-biopharma-conference-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026 https://www.biopharmawatch.com/news/ALEC/alector-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Alector Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PTGX/protagonist-reports-q3-2026-results-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/FLGT/fulgent-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Fulgent Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Puma Biotechnology Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PRTA/prothena-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Prothena Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Tandem Diabetes Care Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GH/guardant-health-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-11-05T21:05:00.000Z Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NTRA/natera-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Natera Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T21:05:00.000Z Nu Skin Enterprises Announces Quarterly Dividend https://www.biopharmawatch.com/news/INGN/inogen-announces-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Inogen Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-q3-2026-results-autonomous-lab-sale BiopharmaWatch en 2026-11-05T21:05:00.000Z Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance https://www.biopharmawatch.com/news/ASTH/astrana-health-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Astrana Health, Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SOLV/solventum-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Solventum Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TXG/10x-genomics-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z 10x Genomics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Castle Biosciences Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CYRX/cryoport-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Cryoport Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HALO/halozyme-reports-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:05:00.000Z HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-05T21:05:00.000Z Tyra Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AORT/artivion-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Artivion Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NUTX/nutex-health-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z NUTEX HEALTH REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/SGHT/sight-sciences-investor-conferences-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Sight Sciences to Present at Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/EQ/equillium-participate-investor-conferences BiopharmaWatch en 2026-11-05T21:05:00.000Z Equillium to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-05T21:05:00.000Z Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MDWD/mediwound-closes-17-25-million-offering BiopharmaWatch en 2026-11-05T21:05:00.000Z MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/RZLT/rezolute-q1-fiscal-2027-results-business-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ICUI/icu-medical-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:05:00.000Z ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Nyxoah Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/MOBI/mobia-medical-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Mobia Medical Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MGNX/macrogenics-participate-investor-conferences-november BiopharmaWatch en 2026-11-05T21:05:00.000Z MacroGenics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-nomlabofusp-icar-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-liver-meeting-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:03:47.000Z Health Catalyst Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SINT/sintx-reports-third-quarter-2026-revenue-growth BiopharmaWatch en 2026-11-05T21:02:29.000Z SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-05T21:02:27.000Z Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:08.000Z Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SPRY/ars-pharma-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:02:01.000Z ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T21:02:00.000Z Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/JANX/janux-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T21:02:00.000Z TransMedics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OMDA/omada-health-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Omada Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/GMED/globus-medical-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-results-corporate-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Celldex Reports Third Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ACH/accendra-health-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Accendra Health Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q3-2026-results-pipeline-progress BiopharmaWatch en 2026-11-05T21:01:00.000Z Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress https://www.biopharmawatch.com/news/NGNE/neurogene-announces-inducement-grant-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-11-05T21:01:00.000Z Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates https://www.biopharmawatch.com/news/INO/inovio-proposed-public-offering-common-stock BiopharmaWatch en 2026-11-05T21:01:00.000Z INOVIO Announces Proposed Public Offering of its Common Stock https://www.biopharmawatch.com/news/RIGL/rigel-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Rigel Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-et-700-pilot-study-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability https://www.biopharmawatch.com/news/ATYR/atyr-pharma-third-quarter-2026-results-update BiopharmaWatch en 2026-11-05T21:01:00.000Z aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update https://www.biopharmawatch.com/news/VYGR/voyager-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Voyager Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/MNKD/mannkind-q3-2026-financial-results-business-update BiopharmaWatch en 2026-11-05T21:01:00.000Z MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-public-offering BiopharmaWatch en 2026-11-05T21:01:00.000Z Orchestra BioMed Announces Proposed Public Offering https://www.biopharmawatch.com/news/CELC/celcuity-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261105 BiopharmaWatch en 2026-11-05T21:01:00.000Z Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q3-2026 BiopharmaWatch en 2026-11-05T21:01:00.000Z Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INAB/in8bio-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-05T21:01:00.000Z IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q3-2026 BiopharmaWatch en 2026-11-05T21:01:00.000Z Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Dentsply Sirona Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ASND/ascendis-report-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 https://www.biopharmawatch.com/news/INGN/inogen-announces-leadership-transition BiopharmaWatch en 2026-11-05T21:00:00.000Z Inogen Announces Leadership Transition https://www.biopharmawatch.com/news/INMB/inmune-bio-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:00:00.000Z INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/TLSA/tiziana-host-investor-call-inform-ms-results BiopharmaWatch en 2026-11-05T19:00:00.000Z Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results https://www.biopharmawatch.com/news/GMAB/genmab-financial-results-nine-months-2026 BiopharmaWatch en 2026-11-05T16:02:00.000Z Genmab Announces Financial Results for the Nine Months of 2026 https://www.biopharmawatch.com/news/BIIB/biogen-update-private-payer-coverage-zurzuvae BiopharmaWatch en 2026-11-05T16:00:00.000Z Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone) https://www.biopharmawatch.com/news/IGC/igc-pharma-alzheimers-agitation-drug-patented BiopharmaWatch en 2026-11-05T15:18:00.000Z IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears https://www.biopharmawatch.com/news/NVO/novo-nordisk-share-trading-disclosure BiopharmaWatch en 2026-11-05T15:02:00.000Z Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-real-world-data-aasld-2026 BiopharmaWatch en 2026-11-05T15:00:00.000Z Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra https://www.biopharmawatch.com/news/ALT/altimmune-reclaim-phase-2-trial-pemvidutide-aasld-2026 BiopharmaWatch en 2026-11-05T15:00:00.000Z Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/VIR/vir-biotechnology-eclipse-1-data-presentation BiopharmaWatch en 2026-11-05T15:00:00.000Z Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call https://www.biopharmawatch.com/news/GILD/gilead-phase-3-ideal-study-results-livdelzi BiopharmaWatch en 2026-11-05T15:00:00.000Z Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) https://www.biopharmawatch.com/news/VSEE/vsee-health-new-hospital-agreements BiopharmaWatch en 2026-11-05T14:30:00.000Z VSee Health Announces 13 New Hospital Agreements Expected to Generate More Than $3 Million in Annual Revenue https://www.biopharmawatch.com/news/MMSI/merit-medical-avf-cohort-wrap-global-registry BiopharmaWatch en 2026-11-05T14:25:00.000Z Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry https://www.biopharmawatch.com/news/KAPA/kairos-pharma-biotech-breakthrough-award-oncology BiopharmaWatch en 2026-11-05T14:15:00.000Z Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-ras-targeted-therapies BiopharmaWatch en 2026-11-05T14:13:00.000Z AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer https://www.biopharmawatch.com/news/SNWV/sanuwave-health-comments-2027-medicare-rate-ultramist BiopharmaWatch en 2026-11-05T14:08:00.000Z Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist https://www.biopharmawatch.com/news/NTHI/neonc-reports-q3-2026-results-and-clinical-progress BiopharmaWatch en 2026-11-05T14:00:16.000Z NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/AMGN/repatha-lowers-heart-attack-risk-study BiopharmaWatch en 2026-11-05T14:00:00.000Z REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY https://www.biopharmawatch.com/news/HIMS/hims-hers-benefits-new-partners-health-support BiopharmaWatch en 2026-11-05T14:00:00.000Z Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most https://www.biopharmawatch.com/news/SBC/shonan-beauty-clinic-newsweek-medical-tourism-2027 BiopharmaWatch en 2026-11-05T14:00:00.000Z Shonan Beauty Clinic Named to Newsweek’s “World’s Best Hospitals & Clinics for Medical Tourism 2027” https://www.biopharmawatch.com/news/ZLAB/zai-lab-zocilurtatug-pelitecan-update BiopharmaWatch en 2026-11-05T14:00:00.000Z Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas https://www.biopharmawatch.com/news/CODX/co-diagnostics-participate-global-tuberculosis-events BiopharmaWatch en 2026-11-05T14:00:00.000Z Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch https://www.biopharmawatch.com/news/POCI/precision-optics-2-million-follow-on-order BiopharmaWatch en 2026-11-05T14:00:00.000Z Precision Optics Announces $2 Million Follow-On Order from Existing Top-Tier Aerospace Customer https://www.biopharmawatch.com/news/IVF/invo-fertility-patientfi-affordable-treatment BiopharmaWatch en 2026-11-05T14:00:00.000Z INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable https://www.biopharmawatch.com/news/MTVA/metavia-da-1726-phase-1-results BiopharmaWatch en 2026-11-05T13:55:00.000Z MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T13:45:00.000Z DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026 https://www.biopharmawatch.com/news/HCWB/hcw-biologics-secures-debt-financing BiopharmaWatch en 2026-11-05T13:45:00.000Z HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing